
Subject Index

A

- A type retrovirus 10
- acute transforming retrovirus 142, 151, 153
- adenocarcinoma 225
- adult T-cell leukemia (ATL) 146
- agar suspension, growth in 155
- alveolar tumours 43–46
- antibodies
 - monoclonal 2, 7
 - polyclonal 2, 7
- anti-MPMV p27 12
- ATL (*see* adult T-cell leukemia)
- autocrine loop 146

B

- B type retrovirus 2, 10, 17, 19
- BAC (*see* human bronchoalveolar carcinoma)
- betaretrovirus 2, 19, 27, 146, 149
- bovine leukemia virus (BLV) 142, 146
- bronchioalveolar carcinoma (*see* human bronchoalveolar carcinoma)

C

- caprine arthritis encephalitis virus 10
- caprine nasal adenocarcinoma virus (CNAV) 202
- capsid protein 7, 11
 - p26 12
- Clara cells 27, 147, 148, 170
- clonality 166
- clone
 - 46.1 14
 - JS 46.1 14

- CNAV (*see* caprine nasal adenocarcinoma virus)
- cytomegalovirus, early promoter 151, 153

D

- D type retrovirus 2, 19
- deltaretrovirus 146
- DF-1 cell 156, 157, 165, 168
- disease nomenclature 41, 42
- dUTPase 16, 17, 90

E

- electron microscopy 42
- ENA (*see* enzootic nasal adenocarcinoma)
- ENA-associated retroviruses 210–219
- endogenous
 - genomes 20
 - JSRV 3, 118–137
 - – age effects 131
 - – chromosomal distribution 123, 124
 - – genomic organization 124–127
 - – loci 125
 - – phylogenetic analysis 127–129
 - – pregnancy effects 131, 132
 - – related proviruses 149, 160
 - – vertebrate distribution 120–123
 - loci 2, 3, 7
 - retrovirus (ERV) 119
 - – evolution 119
 - – human 120, 132
 - – murine 120
- enhancer sequence 145
- ENTV (*see* enzootic nasal tumor virus)
- env* 91

- envelope protein
 – JSRV
 – – surface glycoprotein (SU) 159, 162, 163
 – – transmembrane protein (TM) 160, 162, 163, 167
 – – tyrosine 163
 – – VR3 160, 162, 163
 – surface glycoprotein (SU) 141
 – transmembrane protein (TM) 141
- enzootic nasal
 – adenocarcinoma (ENA) 201–220
 – – clinical features 203–205
 – – immune response 219
 – – macroscopic pathology 205–207
 – – microscopic pathology 207–210
 – tumor virus (ENTV) 16
- epidemiology 73
- ERV (*see* endogenous retrovirus)
- excess secretions 27
- experimental models
 – goats 61
 – mice 61
 – sheep 59
- F**
- 208F cell 155
- fetal sheep 131
- fluorescence in situ hybridization (FISH) 123
- Freon 5, 6, 10, 11
- G**
- gag* 89
- gene therapy 197
- gp55, *Friend* SFFV 159
- Graaf Reinet* disease 9, 10
- gross lesions 31
- growth factor receptor binding protein-2 (grb-2) 163
- H**
- helper virus 143, 153
- HERV K 2, 16
- histological classification 41, 42
- histopathology 36–41
- HNF-3 99, 100
- human
 – bronchoalveolar carcinoma (BAC) 3, 55, 225–244
 – – clinical presentation 231–235
 – – epidemiology 236
 – – lung transplantation 237
 – – pathology 227–231
 – T cell lymphotropic virus
 – – HTLV-I 142, 146
 – – HTLV-II 146
 – tumor 158
- hyaluronidase 158, 168, 190–193
- I**
- Icelandic 1514 visna strain 10
- insertional activation of proto-oncogenes 143, 165, 169
 – enhancer activation 144
 – promoter insertion 143
- intra-bronchiolar proliferations 47
- IS46.1 13
- J**
- jaagsiekte 56, 147
 – sheep retrovirus (JSRV) 1, 16, 27, 55–74, 86, 92, 147, 215, 243
 – – capsid protein 11
 – – cell-mediated immune response 148
 – – genome 16
 – – – organization 149
 – – immune response 69–72
 – – – humoral 148
 – – integration sites 165, 166
 – – LTR 155, 169
 – – molecular biology 149
 – – molecular clone 151
 – – multi-focal tumors 152
 – – and OPA 61
 – – protein expression 63–66
 – – proviral DNA distribution 66
 – – purification 2, 5–7
 – – RNA expression 65
 – – spliced envelope mRNA 155
 – – transformation 153, 156
 – – truncated envelope 156
- JS7 cell 147

- Jsp26 protein 7
 JSRV (*see* jaagsiekte sheep retrovirus)
- L**
 La bouhite 3
 long terminal repeat (LTR) 2, 13, 97, 141
 loss of heterozygosity (LOH) 158
 lung cancer 225
 LV capsid 11
- M**
 mAbs (*see* monoclonal antibodies)
Macaca fascicularis 17
 maedi-visna lentivirus (MVV) 4, 7, 10, 11, 211, 212
 – anti-p30 specific area 12
 Mason-Pfizer monkey virus (MPMV) 7, 11, 89, 149
 MLE-15 97
 MMTV (*see* murine mammary tumor virus)
 MMV 11
 Moloney murine leukemia virus 123
 monoclonal antibodies (mAbs) 2, 7–9, 12
 MPMV (*see* Mason-Pfizer monkey virus)
 MtCC1-2 97
 murine
 – leukemia virus (MuLV) 142, 159, 170
 – – *Friend* 145, 159
 – – *Moloney* 145
 – mammary tumor virus (MMTV) 7, 11, 16, 89, 142, 149, 159, 170
 – – *Sag* 146
 MVV (*see* maedi-visna lentivirus)
- N**
 necropsy 31
 NF κ B 102
 NIH3T3 153
 non-acute retrovirus 143, 151
 Northern blot 12, 13
- O**
 ONAV (*see* ovine nasal adenocarcinoma virus)
- oncogenes, viral 142, 153
 OPA (*see* ovine pulmonary adenocarcinoma)
orf-x 2, 16, 90, 91, 104, 149, 152, 155
 ovine
 – interstitial pneumonia 9
 – nasal adenocarcinoma virus (ONAV) 152, 214–216
 – – Env 218, 219
 – pulmonary adenocarcinoma (adenomatosis; OPA) 1, 3, 9–11, 20, 56, 147, 240–242
 – – age distribution 57
 – – geographic distribution 57
 – – neoplastic cells 67
 – – prevalence 58
 – – atypical 33, 34
 – – epidemiological studies 73, 74
 – – experimental models 59–61
 – – geographic distribution 57–59
 – – goats 31, 35, 41
 – – Incubation 60
 – – moufflon 31, 35, 41
 – – neoplastic cells 67, 68
 – – pathology 25–50
 – – sheep 28–30, 42
- P**
 p53 226
 PAK 160
 PCR 27
 phosphatidyl
 – inositol 3-kinase (PI 3K) 163, 168
 – inositol-dependent kinase 1 (PDK-1) 164
pol 90
 polyclonal antibodies 2, 7, 12
pro gene 90
 proto-oncogenes 143, 239, 240
 pulmonary
 – adenomatosis, sheep (SPA) 3, 4
 – carcinoma, ovine 3
 purified virus 7, 10
- R**
 radiation hybrid cell lines 185, 187–190
ras 226

- Rat6 cell 155
 RCAS vector 157, 165
 recombination 118, 127
 replication cycle, retrovirus 140
 retroviral vectors
 – JSRV 185–188
 – ONAV 185–187
 retrovirus
 – A type 10
 – B type 2, 10, 14, 17, 19
 – D type 2, 14, 19
 – Env proteins 180, 181
 – receptors
 – – identification 183–185
 – – JSRV 187–192, 194–196
 – – known 180–182
 – – ONAV 194–196
 reverse transcriptase
 – activity 4–6, 10, 12
 – assay 5
 Rex, HTLV 146
 Rous sarcoma virus 142
 RT assay 16
- S**
 SA- OMVV (*see* South African ovine
 maedi visna virus)
 SFFV (*see* spleen focus-forming virus)
 SH-2 domain 163
 sheep
 – pulmonary adenomatosis (SPA) 3, 4,
 56
 – tumours 27
 sheep/hamster hybrid cell lines 166
 signal peptide 92
 Simian immunodeficiency virus (SIV)
 160
 – Nef 160
 – SIVmacPBJ14 160
 South African ovine maedi visna virus
 (SA-OMVV) 10, 13
 – genome 12
 SPA (*see* sheep pulmonary adenomatosis)
 spleen focus-forming virus (SFFV) 159
 surfactant protein A (SPA) 153, 166
- T**
 293 T cell 151
 T cell ontogeny 2, 19
 TATA box 97
 Tax, HTLV 146
 taxonomy 84–86
 tissue structures 48
 Toll-like receptor 4 (TLR-4) 159, 170
 transmission 4, 10
 transmission
 – electron microscopy 6, 10
 tumor suppressors 158, 193, 196–197,
 238
 type B retrovirus 2, 10, 14, 17, 19
 type B/D retroviruses 12
 type D retrovirus 2, 14, 19
 type D/B retrovirus 16
 type II pneumocyte 27, 147, 148, 164,
 167, 170
- U**
 uterus 129
- V**
 viral particles, morphology 48–50
 visna virus p30 capsid 11
 VR1 160
 VR2 160